Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach

@article{Grnwald2010ManagementOS,
  title={Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach},
  author={Viktor Gr{\"u}nwald and Daniel Kalanovic and Axel Stuart Merseburger},
  journal={World Journal of Urology},
  year={2010},
  volume={28},
  pages={343-351}
}
The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients. Based on its clinical activity, disease control over a period of 11 months can be expected with sunitinib treatment. Given this prolonged period of exposure to sunitinib, adverse events tend to reoccur and can possibly decrease the quality of life in… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management

JG Desai, H Pavlakis, N McAarthur, ID GADavis
Asia-PaciWc Journal of Clinical Oncology • 2007
View 10 Excerpts
Highly Influenced

Optimisation of sunitinib therapy in metastatic renal cell carcinoma: Adverse-event management

S Negrier, A Ravaud
Eur J Cancer Suppl • 2007
View 4 Excerpts
Highly Influenced

Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada • 2007
View 9 Excerpts
Highly Influenced

SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2001
View 4 Excerpts
Highly Influenced

Management of hypertension in angiogenesis inhibitor-treated patients.

Annals of oncology : official journal of the European Society for Medical Oncology • 2009
View 1 Excerpt

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…